Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 6/20 | 0.48 |
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP9 | P14780 | 6/20 | 0.48 |
| ▸ | MMP8 | P22894 | 6/20 | 0.48 |
| ▸ | MMP13 | P45452 | 6/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4946002 | 0.89 | CNR2 (0.65) | CNR2ALDH1A1 | |
| SCHEMBL5048052 | 0.88 | CNR2 (0.75) | CNR2 | |
| SCHEMBL5050411 | 0.84 | TAS2R14 (0.58) | CNR2ALDH1A1CXCR3 | |
| SCHEMBL5047940 | 0.83 | MAPT (0.64) | CNR2KMT2AMAPTCXCR3 | |
| SCHEMBL5725098 | 0.82 | ALDH1A1 (0.54) | CNR2ALDH1A1 | |
| SCHEMBL5050520 | 0.82 | TAS2R14 (0.56) | CNR2ALDH1A1KMT2A | |
| SCHEMBL4947264 | 0.81 | ALDH1A1 (0.55) | CNR2ALDH1A1 | |
| SCHEMBL5050460 | 0.81 | CNR2 (0.49) | CNR2ALDH1A1 | |
| SCHEMBL4948807 | 0.80 | PTGER2 (0.56) | CNR2 | |
| SCHEMBL5725083 | 0.80 | ALDH1A1 (0.54) | CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| CN-1859903-A | Use of EP2 selective receptor agonists in medical treatment | PFIZER PROD INC (US) | 2006-11-08 | — | — | CN | disclosed |
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PFIZER INC. | 2005-09-15 | — | — | US | disclosed |
| US-20030078261-A1 | Prostaglandin agonists | CAMERON KIMBERLY O (US) | 2003-04-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203086-A1 | Methods of treatment using an EP2 selective receptor agonist | PTGER2, PTGES2, PTGFR | CNR2 244/4885MAPK1 2626/4885ALDH1A1 3293/4885 |
| US-20030078261-A1 | Prostaglandin agonists | PTGER1, PTGER4, PTGIR | CNR2 373/4885MAPK1 2397/4885ALDH1A1 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.